MICs of Bay 12-8039 and comparative antimicrobials were determined for 820 recent clinical isolates. Ciprofloxacin was Ϸ2-fold more active than Bay 12-8039 and ofloxacin against Enterobacteriaceae and Ϸ8-fold more active against Pseudomonas aeruginosa. Bay 12-8039 was Ϸ2-to 16-fold more active than ciprofloxacin and ofloxacin against nonfermenters (except P. aeruginosa), staphylococci, streptococci, enterococci, and anaerobes. As determined by regression analysis, there was a high degree of correlation among quinolone MICs.
Bay 12-8039 is a new 8-methoxyquinolone with a broad antibacterial spectrum (11) . In this study, the MICs of Bay 12-8039, ciprofloxacin, ofloxacin, amoxicillin-clavulanate, cefuroxime, loracarbef, ceftriaxone, and clarithromycin were determined for 820 recent clinical isolates from Columbus, Ohio. Frequency distribution curves and regression analyses were used to compare quinolone MICs.
Organisms. The organisms studied included 820 bacterial strains arbitrarily selected from among fresh clinical isolates at the Ohio State University Medical Center during the course of the study, April to December 1996. Duplicate isolates from individual patients were excluded.
Antimicrobial agents. Bay 12-8039 and ciprofloxacin were obtained from Bayer Corp., West Haven, Conn., ofloxacin was obtained from R. W. Johnson Pharmaceutical Research Institute, Raritan, N.J., amoxicillin-clavulanate was obtained from Beecham Laboratories, Bristol, Tenn., cefuroxime and loracarbef were obtained from Eli Lilly and Co., Indianapolis, Ind., ceftriaxone was obtained from Hoffmann-La Roche Inc., Nutley, N.J., and clarithromycin was obtained from Abbott Laboratories, Abbott Park, Ill.
Laboratory standard powders were diluted in accordance with manufacturers' recommendations and were then dispensed into microdilution plates in log 2 dilution steps with various ranges with a Quick Spense II dispensing machine (Dynatech Laboratories, Inc., Chantilly, Va.). Plates were stored at Ϫ70°C until they were used.
Susceptibility tests. MICs for nonfastidious organisms and Haemophilus influenzae were determined by a standardized microdilution method (7) in 0.1-ml volumes of cation-adjusted Mueller-Hinton broth (Difco Laboratories, Detroit, Mich.) and Haemophilus Test Medium, respectively. For Streptococcus pneumoniae, cation-adjusted Mueller-Hinton broth with 5% lysed horse blood was used. Incubation was in room air for approximately 20 h. For anaerobes, the medium was Schaedler broth (Difco) supplemented with 1% heat-inactivated horse serum and 0.5 g of vitamin K 1 per ml; incubation was in 85% N 2 -10% H 2 -5% CO 2 for approximately 48 h (8) . Microdilution plates were inoculated with disposable inoculators (Dynatech) so that the final inoculum was approximately 5 ϫ 10 5 CFU/ml. Recommended control strains (7-9) were used. MIC breakpoints for defining susceptibility, intermediate susceptibility, and resistance were those recommended by manufacturers and the National Committee for Clinical Laboratory Standards (9) .
The MICs of the eight study drugs and the percentages of strains susceptible to the bacterial species studied are shown in Table 1 . Control strains and their Bay 12-8039 MICs were as follows: Escherichia coli ATCC 25922, 0.03 to 0.06 g/ml (n ϭ 9); Pseudomonas aeruginosa ATCC 27853, 2 g/ml (n ϭ 9); Staphylococcus aureus ATCC 29213, 0.03 to 0.06 g/ml (n ϭ 9); Enterococcus faecalis ATCC 29212, 0.12 to 0.25 g/ml (n ϭ 8); Bacteroides fragilis ATCC 25285, 0.12 g/ml (n ϭ 3); and Bacteroides thetaiotaomicron ATCC 29741, 0.5 to 1 g/ml (n ϭ 4).
The results of this study, which used strains from the United States, were similar to those recently reported from the United Kingdom (11) , although the nonfermenters from the United States were more resistant to quinolones than those from the United Kingdom. Bay 12-8093, like all quinolones, had marked activity against H. influenzae and Moraxella catarrhalis. It was less active than ciprofloxacin and comparable in activity to ofloxacin against Enterobacteriaceae and P. aeruginosa. It was more active than both ciprofloxacin and ofloxacin against common nonfermenters (other than P. aeruginosa), staphylococci, streptococci, enterococci, and anaerobes. The in vitro activity of Bay 12-8039 was quite similar to that of another new quinolone, trovafloxacin (5, 11) . The activities of the nonquinolone antibiotics were better than those of the quinolones against some species; ceftriaxone was better against Morganella morganii, Providencia stuartii, and Acinetobacter baumannii, and amoxicillin-clavulanate was better against Enterococcus faecalis and anaerobes.
Organisms which have been problematic in the United States, including Providencia stuartii, methicillin-resistant coagulase-negative staphylococci, pneumococci with reduced penicillin susceptibility, and vancomycin-resistant enterococci, were not included in the United Kingdom study (11) . Bay 12-8039 was more active than ciprofloxacin and ofloxacin against all of these organisms, but most (except the pneumococci) were relatively quinolone resistant. The pneumococci were uniformly susceptible to all three quinolones regardless of penicillin susceptibility.
MIC frequency distribution curves and regression analyses. MICs were entered into a Macintosh model 7500/100 computer with File Maker Pro software. Quinolone MICs were converted to log 2 values and then exported to Cricket Graph III. MIC frequency distribution curves were drawn, and regression lines of best fit were calculated for selected species and groups of similar species. The formula for the latter was y ϭ ax ϩ b, where x is the ciprofloxacin MIC (log 2 ), a is the slope, b is the y-intercept, and y is the Bay 12-8039 or ofloxacin MIC (log 2 ). r 2 , the coefficient of determination, indicated the proportion of the total variance in y which could be explained by the variance in x. For example, if r 2 ϭ 0.85, 85% of the total variance in the MIC of Bay 12-8039 or ofloxacin was determined by the MIC of ciprofloxacin.
There was a bimodal distribution of quinolone MICs for many of the species studied. Frequency distribution curves for selected species or groups of similar species are shown in Fig. 1 .
In Table 2 , regression analyses are used to compare Bay 12-8039 and ofloxacin MICs to ciprofloxacin MICs. Despite differences in activities against various species, there were high degrees of correlation among quinolone MICs; slopes of regression lines comparing MICs (log 2 ) were close to unity, and coefficients of determination were usually Ͼ0.85. This has been the case with other quinolones (1-4, 6, 10). The relative differences in activities against various spe- Continued on following page Continued on following page 
